Aquestive Therapeutics, Inc. AQST Cash ratio
Cash ratio at other companies
Other financials
Where this comes from
Calculated from Aquestive Therapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s cash ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s cash ratio?
- Aquestive Therapeutics, Inc. (AQST) reported cash ratio of 3.5× in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s cash ratio changed year-over-year?
- Aquestive Therapeutics, Inc.'s cash ratio decreased by 7.1% year-over-year, from 3.8× to 3.5×.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s cash ratio?
- Over 5 years (2020 to 2025), Aquestive Therapeutics, Inc.'s cash ratio has grown at a 11.0% compound annual growth rate (CAGR), from 1.5× to 2.5×.
- What does cash ratio mean?
- Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.